<DOC>
	<DOCNO>NCT01968616</DOCNO>
	<brief_summary>In retinal vein occlusion , predictive factor visual outcome ranibizumab treatment evaluate comprehensively . Therefore , plan analyze predictor visual outcome viewpoint electrophysiology biomarkers besides morphological feature SD-OCT .</brief_summary>
	<brief_title>Ranibizumab Treatment Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent form Male female age 18 year old Macula edema secondary BRVO/CRVO Decrease VA due macular edema Prior episode RVO Previous treatment antiVEGF drug corticosteroid grid laser photocoagulation ( study eye ) Ocular disorder study eye may confound interpretation study result History vitrectomy surgery , submacular surgery , surgical intervention RVO The pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>